Psilocybine and Clinical Development

Psilocybin is currently being extensively studied as a potential therapeutic agent for multiple psychiatric disorders. Here, a systematic literature review of all published pharmacokinetic data on the pharmacologically active metabolite of psilocybin, psilocin, is presented. The review includes clinical studies that reported pharmacokinetic data an...

Psilocin is a well-studied controlled substance with potential psychotherapeutic applications. However, research gaps remain regarding its metabolism. Our objective was to elucidate a comprehensive Phase I metabolic profile of psilocin to support its forensic management and clinical development. We utilized human enzymes from various sources to cha...

Although the development of psilocybin therapy has come as a surprise to many, modern research with the drug has been ongoing for 25 years. Psilocybin therapy is composed of psilocybin dosing sessions embedded within a wider process of psychoeducation, psychological support and integration. Early phase clinical trial evidence is promising, particul...

Research on classical psychedelics (psilocybin, LSD and DMT) and entactogen, MDMA, has produced a renaissance in the search for more effective drugs to treat psychiatric, neurological and various peripheral disorders. Psychedelics and entactogens act though interaction with 5-HT 2A and other serotonergic receptors and/or monoamine reuptake transpor...

Psilocin is the active metabolite of psilocybin, a serotonergic psychedelic substance. It is used recreationally and investigated in substance-assisted psychotherapy. The pharmacokinetic properties of psilocin are only partially characterized. Therefore, we developed and validated a rapid LC-MS/MS method to quantify psilocin and its metabolite 4-hy...

The medium to long term consequences of COVID-19 are not yet known, though an increase in mental health problems are predicted. Multidisciplinary strategies across socio-economic and psychological levels may be needed to mitigate the mental health burden of COVID-19. Preliminary evidence from the rapidly progressing field of psychedelic science, sh...

Psilocybin is a psychedelic tryptamine currently being evaluated clinically for its ability to improve the symptoms of major depressive disorder (MDD). As part of a program to fully characterize psilocybin active pharmaceutical ingredient (API) that will be used for clinical development activities, a polymorph screen involving over 150 solvent and...

Background: Conventional antidepressants are thought to produce their impact on clinical symptoms by increasing the central availability of biogenic amine neurotransmitters (the monoamine hypothesis of depression). These drugs continue to be the primary medicines used in major depressive disorder. Although they have biological effects after acute...

Clinical research is inhibited by the legal status of many potentially useful psychoactive substances. Thus drugs in Schedule 1 of the UK Misuse of Drugs Regulations (e.g. LSD [lysergide], MDMA [3,4-methylenedioxymethamphetamine] and psilocybin) are considered to have no medicinal use. Not only is there a considerable cost in obtaining suitable lic...